Rhinogram vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 35)
Rhinogram logo

Rhinogram

EmergingHealthTech

Patient Communication

Rhinogram is a HIPAA-compliant patient communication platform enabling healthcare providers to text, video chat, and send forms to patients using their existing office phone number.

AI VisibilityBeta
Overall Score
D35
Category Rank
#535 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
29
Gemini
31

About

Rhinogram provides healthcare practices with a HIPAA-compliant messaging platform that allows clinical and administrative staff to communicate with patients via text message, secure video, and digital forms using the practice's existing landline or VoIP phone number — without sharing personal staff cell numbers. Patients text the office number they already have, and staff manage all conversations through a unified web and mobile inbox that supports multiple simultaneous conversations, message templates, and team assignments.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

35
Overall Score
90
#535
Category Rank
#2
87
AI Consensus
83
stable
Trend
stable
31
ChatGPT
92
29
Perplexity
93
31
Gemini
89
34
Claude
96
34
Grok
95

Key Details

Category
Patient Communication
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Rhinogram
Patient Communication

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.